Reduced FOXO3 activity has been linked to resistance to androgen deprivation therapy, whereas increased FOXO3 expression has demonstrated the ability to enhance the sensitivity of prostate cancer cells to this therapy. This evidence concerns the gene FOXO3 and prostate carcinoma.